Leadership Team

Astex Pharmaceuticals is led by a globally experienced management team with knowledge and expertise in finance, drug discovery, development and commercialization.

  • Astex, Cambridge, UK
    +/-

    • Harren JhotiPhD, President and CEO, Astex Therapeutics Limited
      +/-

      Harren Jhoti co-founded Astex Therapeutics Limited in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. He also served as president and member of the Board of Directors of Astex Pharmaceuticals Inc., following the merger of Astex Therapeutics Limited with SuperGen Inc., (subsequently renamed Astex Pharmaceuticals Inc.) in July 2011. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served as a non-executive director of Iconix Inc. and currently serves on the board of the BIA, the UK BioIndustry Association. Before founding Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.

    • Martin BucklandDPhil, MBA, Chief Business Officer
      +/-

      Joined Astex Therapeutics as chief business officer in September 2004 and served as a member of the Board of Directors from July 2008 through the merger with SuperGen Inc. to create Astex Pharmaceuticals, Inc., in July 2011. He has more than 20 years of commercial and business development experience in the pharmaceutical industry and joined Astex from Elan Pharmaceuticals, where he previously held the position of vice president of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. He has a BA in Chemistry and a DPhil from the University of Oxford, and an MBA from the Open Business School.

    • Lyn LeaperEPA, PhD, Senior Vice President, Corporate Development
      +/-

      Joined Astex Therapeutics as vice president, Intellectual Property, in October 2002. She is a European patent attorney who joined Astex from StratagemIPM where she provided IP management and strategic advice to medical and biotechnology companies. Previously, she worked at Akzo Nobel NV and from 1999 was director of patents at Janssen Pharmaceutica NV (a Johnson & Johnson Company). She obtained a BSc in Biochemistry and a PhD in Plant Biochemistry and Molecular Biology before commencing a career in intellectual property at The Wellcome Foundation Ltd in 1988.

    • Neil ThompsonPhD, Senior Vice President, Biology
      +/-

      Joined Astex Therapeutics as vice president of Biology in January 2002 from GlaxoSmithKline where he was director of the Immunology Platform responsible for specialist cellular and molecular immunology employed in the drug development process. Previously, as head of the Cellular Immunology Unit, he provided support for both small molecule and therapeutic vaccine programs and has led several drug discovery projects in a variety of therapeutic areas. Prior to this, he was a senior biochemist with Wellcome Research Laboratories. He received his doctorate in Biochemistry from King's College, London, in 1985.

    • David ReesPhD, Senior Vice President, Chemistry
      +/-

      Joined Astex Therapeutics in January 2003. Prior to Astex, Dr. Rees had 19 years of experience as a medicinal chemist in the pharmaceutical industry, working with Parke-Davis, Organon and, most recently, AstraZeneca, where he held the position of director and head of the Medicinal Chemistry Department with some 140 staff, at the research and development laboratories in Mölndal, Sweden. He is a co-recipient of the Royal Society of Chemistry Malcolm Campbell Memorial Prize 2007 for the discovery of the anesthesia drug sugammadex (Bridion). He is a co-author of over 80 publications and patents and has served as an honorary professor at Glasgow University and as president of the RSC Organic Division.

  • Astex, California, USA
    +/-

    • Mohammad AzabMD, MSc, MBA, President and Chief Medical Officer, Astex Pharmaceuticals Inc.
      +/-

      Joined Astex Pharmaceuticals (formerly SuperGen) as chief medical officer in July 2009. He possesses more than 25 years of experience in worldwide drug development, clinical research and medical affairs. Previously, Dr. Azab served as president and CEO of Intradigm Corporation, a privately held Palo Alto, California, company developing siRNA cancer therapeutics. Prior to this, Dr. Azab served as executive vice president of Research and Development, and chief medical officer of Vancouver, British Columbia-based QLT Inc., where he led clinical development for now-approved drugs in oncology, gastrointestinal and ophthalmologic indications including Visudyne®, first drug ever approved for the treatment of Age-related macular degeneration. He also served as Oncology Drug Team leader at UK-based Zeneca Pharmaceuticals, now AstraZeneca, where he held responsibilities in global clinical development for oncology drugs including Arimidex® in Breast Cancer. Before Zeneca, Dr. Azab was an international medical manager in oncology at Sanofi Pharmaceuticals, in Gentilly, France. Dr. Azab received his medical degree in 1979 from Cairo University. He practiced and received his postgraduate training as a medical oncologist in France at Institut Gustave Roussy where he earned degrees in oncology research and statistics from the University of Paris-Sud in 1986 and the University of Pierre and Marie Curie in 1992. He has published more than 100 medical papers and abstracts including publication in New England Journal of Medicine. He is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society of Hematology, the International Association for the study of Lung Cancer, and the European Society of Medical Oncology. Dr. Azab received an MBA, with Distinction, from the Richard Ivey School of Business, University of Western Ontario in 2001.

    • Sanjeev RedkarPhD, MBA, Senior Vice President of Pharmaceutical Development & Manufacturing
      +/-

      Joined Astex Pharmaceuticals (formerly SuperGen) in 1998 with responsibility for Process Development. Over the years he has had increased areas of responsibility in Pharmaceutical Development and Manufacturing. Dr. Redkar has over 20 years of oncology drug development experience working previously at Matrix Pharmaceutical. Dr. Redkar completed his undergraduate degree at the Indian Institute of Technology, Bombay; PhD in Chemical Engineering from University of Colorado, Boulder; and MBA from St. Mary’s College of California. Dr Redkar is on the Adjunct faculty at the University of the Pacific, Stockton and on their Industrial Advisory Board.